Doxorubicin Market Growth, Size, Share, Trends, Key Players Analysis, and Forecast by 2031

Doxorubicin Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Formulation (Lyophilized Powder and Doxorubicin Injection), Application (Breast Cancer, Kidney Cancer, Liver Cancer, Sarcoma, Ovarian Cancer, Lung Cancer, Leukemia, Multiple Myeloma, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)

  • Report Code : TIPRE00011780
  • Category : Pharmaceuticals
  • No. of Pages : 150
Buy Now

Doxorubicin Market Strategic Insights and Updates by 2031

Buy Now

The doxorubicin market size is projected to reach US$ 2.35 billion by 2031 from US$ 1.47 billion in 2023. The market is expected to register a CAGR of 6.1% during 2023–2031. The increasing approval of generic products is likely to remain a key trend in the doxorubicin market.

Doxorubicin Market Analysis

Factors such as increasing preference for chemotherapy and rising prevalence of cancer are driving the market growth. Moreover, the increasing government funding, guidance, and technical assistance for cancer prevention is providing significant opportunities for the future growth of the doxorubicin market players.

Doxorubicin Market Overview

Doxorubicin is used in chemotherapy to treat a different type of cancers, including bladder cancer, breast cancer, lymphoma, and other. It is injected intravenously alongside other chemotherapy medicines and is marketed under various brand names, including Adriamycin and Caelyx, among others. Adriamycin is a popular anthracycline chemotherapy medication that inhibits the development of cancer cells.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Doxorubicin Market: Strategic Insights

Doxorubicin Market

  • CAGR (2023 - 2031)
    6.1%
  • Market Size 2023
    US$ 1.47 Billion
  • Market Size 2031
    US$ 2.35 Billion

Market Dynamics

GROWTH DRIVERS
  • Increasing Prevalence of Cancer
  • Increasing Preference for Chemotherapy
FUTURE TRENDS
  • Introduction of Nanaomaterials in Cancer Treatment is the New Trends Witnessed in the Market
OPPORTUNITIES
  • Increasing Government Funding and Grants

Key Players

  • Accord Healthcare
  • Cipla Inc.
  • Dr. Reddy's Laboratories
  • Meiji Holdings Co. Ltd.
  • Janssen Pharmaceuticals (Johnson and Johnson Services, Inc.)
  • Novartis AG
  • Pfizer Inc
  • Sun Pharmaceutical Industries Ltd
  • Baxter International Inc.
  • Zydus Cadila

Regional Overview

  • North America
  • Europe
  • Asia-Pacific
  • South and Central America
  • Middle East and Africa

Market Segmentation

Drug Formulation
  • Lyophilized Powder
  • Doxorubicin Injection
Application
  • Breast Cancer
  • Kidney Cancer
  • Liver Cancer
  • Sarcoma
  • Ovarian Cancer
  • Lung Cancer
  • Leukemia
  • Multiple Myeloma
Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Doxorubicin Market Drivers and Opportunities

Increasing Preference for Chemotherapy Favors Market Growth

Spending on anticancer drugs is essential to incurring excess healthcare costs. Both targeted therapy and chemotherapy significantly improve cancer patient's chances of survival. These therapies may bring about the complete reduction of a tumor. The demand for chemotherapy has surged globally, owing to the benefits. According to an article published in Lancet Oncology, the number of patients requiring chemotherapy will rise by 53% from 2018 to 2040. Advanced cancer treatments improve patient survival and increase long-term outpatient chemotherapy requirements. More exposure to chemotherapy results in a greater demand for doxorubicin drugs, thereby boosting the market growth.

Increasing Government Funding and Grants to Create Notable Opportunities in Future

Many programs have started by various countries for effective and rapid treatment for cancer. For instance, in June 2020, the University of Missouri School of Medicine received  a grant of nearly US$ 3.5 million from the National Institutes of Health to study a pre-treatment for chemotherapy that might protect the patients of cancer suffering from therapy-induced heart complications. Thus, increasing government support as grants and assistance are supporting significant growth opportunities for the doxorubicin drug manufacturers.

Doxorubicin Market Report Segmentation Analysis

Key segments that contributed to the derivation of the doxorubicin market analysis are drug formulation, application and distribution channel.

  • By drug formulation, the market is bifurcated into lyophilized powder and doxorubicin injection. In 2023, the lyophilized powder segment held a larger share of the market.
  • Based on application, the doxorubicin market is segmented into lung cancer, sarcoma, breast cancer, multiple myeloma, ovarian cancer, kidney cancer, leukemia, liver cancer, and others. In 2023, the breast cancer segment held the largest share of the market. The kidney cancer segment is estimated to register the highest CAGR during the forecast period.
  • In terms of distribution channel, the market is divided into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held a significant share of the market in 2023.

Doxorubicin Market Share Analysis by Geography

The geographic scope of the doxorubicin market report encompasses five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America. North America dominated the doxorubicin market in 2023. The continuous growth in the pharmaceutical industry, rising prevalence of various cancers, and increasing R&D initiatives by the key players are the driving factors for the doxorubicin market in North America, which are propelling the market's expansion in this region.

Doxorubicin Market Report Scope

Report Attribute Details
Market size in 2023 US$ 1.47 Billion
Market Size by 2031 US$ 2.35 Billion
Global CAGR (2023 - 2031) 6.1%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Drug Formulation
  • Lyophilized Powder
  • Doxorubicin Injection
By Application
  • Breast Cancer
  • Kidney Cancer
  • Liver Cancer
  • Sarcoma
  • Ovarian Cancer
  • Lung Cancer
  • Leukemia
  • Multiple Myeloma
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Accord Healthcare
  • Cipla Inc.
  • Dr. Reddy's Laboratories
  • Meiji Holdings Co. Ltd.
  • Janssen Pharmaceuticals (Johnson and Johnson Services, Inc.)
  • Novartis AG
  • Pfizer Inc
  • Sun Pharmaceutical Industries Ltd
  • Baxter International Inc.
  • Zydus Cadila
    • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

    Doxorubicin Market News and Recent Developments

    The doxorubicin market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the market are mentioned below:

    • Zydus Cadila has received final approval from the USFDA to market Doxorubicin Hydrochloride Liposome Injection (US RLD: Doxil Liposome Injection) in the strengths of 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials. (f Zydus Cadila, Press Release, September 2020)

    Doxorubicin Market Report Coverage and Deliverables

    The “Doxorubicin Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering the following areas:

    • Root canal market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
    • Root canal market trends as well as market dynamics such as drivers, restraints, and key opportunities
    • Detailed PEST/Porter’s Five Forces and SWOT analysis
    • Root canal market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the doxorubicin market
    • Detailed company profiles
    Report Coverage
    Report Coverage

    Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

    Segment Covered
    Segment Covered

    Drug Formulation, Application, and Distribution Channel

    Regional Scope
    Regional Scope

    North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

    Country Scope
    Country Scope

    Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States

    Frequently Asked Questions


    Which region dominated the doxorubicin market in 2023?

    North America dominated the market in 2023.

    What are the factors driving the doxorubicin market growth?

    Increasing prevalence of cancer and increasing preference for chemotherapy are the major factors bolstering the market.

    What would be a prominent future trend in the doxorubicin market?

    The increasing approval of generic products is likely to emerge as a significant trend in the market in the future.

    Which are the leading players operating in the doxorubicin market?

    Accord Healthcare, Cipla Inc., Dr. Reddy's Laboratories, Meiji Holdings Co. Ltd., Janssen Pharmaceuticals (Johnson and Johnson Services, Inc.), Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd, Baxter International Inc., Zydus Cadila are the leading players operating in the doxorubicin market.

    What would be the estimated value of the doxorubicin market by 2031?

    The estimated value of the market by 2031 will be US$ 2.35 billion.

    What would be the expected CAGR of the doxorubicin market?

    The market is estimated to record a CAGR of 6.1% during 2023–2031.

    Trends and growth analysis reports related to Pharmaceuticals : READ MORE..